Morgan Stanley Bolt Biotherapeutics, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 24,687 shares of BOLT stock, worth $18,268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,687

Previous 79,394 68.91%

Holding current value

$18,268

Previous $88,000 61.36%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.01 - $1.4 $55,254 - $76,589	-54,707 Reduced 68.91%	24,687 $34,000
Q4 2023 Feb 13, 2024	SELL	$0.85 - $1.12 $68,317 - $90,018	-80,374 Reduced 50.31%	79,394 $88,000
Q3 2023 Nov 15, 2023	BUY	$0.98 - $1.46 $123,675 - $184,250	126,199 Added 375.94%	159,768 $166,000
Q2 2023 Aug 14, 2023	SELL	$1.27 - $1.95 $346,497 - $532,024	-272,833 Reduced 89.04%	33,569 $42,000
Q1 2023 May 15, 2023	BUY	$1.29 - $1.66 $350,259 - $450,721	271,519 Added 778.37%	306,402 $425,000

Q4 2022 Feb 14, 2023	SELL	$1.26 - $1.48 $45,562 - $53,518	-36,161 Reduced 50.9%	34,883 $45,000
Q3 2022 Nov 14, 2022	SELL	$1.72 - $2.61 $584,502 - $886,948	-339,827 Reduced 82.71%	71,044 $105,000
Q2 2022 Oct 27, 2022	SELL	$1.41 - $2.91 $18,217 - $37,597	-12,920 Reduced 3.05%	410,871 $838,000
Q2 2022 Aug 15, 2022	SELL	$1.41 - $2.91 $18,217 - $37,597	-12,920 Reduced 3.05%	410,871 $838,000
Q1 2022 Oct 27, 2022	BUY	$2.74 - $4.82 $35,400 - $62,274	12,920 Added 3.14%	423,791 $1.16 Million
Q1 2022 May 13, 2022	SELL	$2.74 - $4.82 $74,848 - $131,667	-27,317 Reduced 6.06%	423,791 $1.16 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $13.97 $1.13 Million - $3.76 Million	268,831 Added 147.48%	451,108 $2.21 Million
Q3 2021 Nov 15, 2021	BUY	$11.15 - $18.6 $2.03 Million - $3.39 Million	182,277 New	182,277 $2.31 Million

Others Institutions Holding BOLT

# of Institutions

Shares Held

24.3M

Call Options Held

Put Options Held

View Full List

About Bolt Biotherapeutics, Inc.

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $27.9M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

More about BOLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account